Late-Window Stroke: Hyperglycemia Doesn’t Alter EVT Benefit
The International Journal of Stroke recently shared a post on X:
”Just Accepted! Study in those with acute ischemic stroke and large vessel occlusion of the anterior circulation. Results show hyperglycaemia does not modify the efficacy of endovascular therapy in the late time window.”
Read the full article here.
Hyperglycemia has long been the unwelcome guest at the stroke table, often associated with worse outcomes and suspected of meddling with treatment effects—especially in early endovascular therapy (EVT).
Naturally, one might expect it to play a similarly disruptive role in patients treated in the late window (6 to 24 hours after symptom onset or last known well).
But in the study of anterior circulation large vessel occlusion stroke, Clemens Kersten et al. showed that hyperglycemia had surprisingly little to say.
Regardless of admission glucose levels, the benefit of EVT remained unchanged.
In conclusion, no evidence that admission glucose or hyperglycemia modifies the benefit of EVT in this population, suggesting EVT efficacy remains consistent across a range of glucose levels in the late window setting.
Stay updated on the advancements in science in the field of thrombosis with Hemostasis Today.
-
Mar 11, 2026, 18:27Cesar Garrido and Lackram Bodoe Are Advancing WFH Partnerships in Trinidad and Tobago
-
Mar 11, 2026, 18:14Aloke Finn: Silent Plaque Rupture and Healing in Coronary Artery Disease
-
Mar 11, 2026, 17:23Mattia Galli: A Privilege to Collaborate on Such a Complex Topic as Cardio-Rheumatology
-
Mar 11, 2026, 17:12Shubham Misra: Proteomic Biomarkers for Acute Stroke Subtype Classification
-
Mar 11, 2026, 16:55Melanie Daniel: Modeling High-Purity von Willebrand Factor for Individualized Dosing in Surgery
-
Mar 11, 2026, 15:46Bleeding and Thrombosis Outcomes in Older Patients With Myelodysplastic Syndromes – JTH
-
Mar 11, 2026, 15:37Sonia Muliyil: The Greatest Benefit is The Wellbeing and Sustenance of Half The World’s Population
-
Mar 11, 2026, 15:34Kymentie Ferdinande: Rivaroxaban in Cirrhosis and the Path Toward Individualized Anticoagulation
-
Mar 11, 2026, 15:34Sheharyar Raza: When More Testing Isn’t Always Better in Healthy Donor Screening